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Background: Idiopathic pulmonary hemosiderosis (IPH) is a rare cause of alveolar hemorrhage in children and its
pathophysiology remains obscure. Classically, diagnosis is based on a triad including hemoptysis, diffuse
parenchymal infiltrates on chest X-rays, and iron-deficiency anemia. We present the French pediatric cohort of IPH
collected through the French Reference Center for Rare Lung Diseases (RespiRare®, www.respirare.fr).
Methods: Since 2008, a national network/web-linked RespiRare® database has been set up in 12 French pediatric
respiratory centres. It is structured as a medical recording tool with extended disease-specific datasets containing
clinical information relevant to all forms of rare lung diseases including IPH.
Results: We identified 25 reported cases of IPH in children from the database (20 females and 5 males). Among them,
5 presented with Down syndrome. Upon diagnosis, median age was 4.3 [0.8-14.0] yrs, and the main manifestations
were: dyspnea (n = 17, 68%), anemia (n = 16, 64%), cough (n = 12, 48%), febrile pneumonia (n = 11, 44%) and
hemoptysis (n = 11, 44%). Half of the patients demonstrated diffuse parenchymal infiltrates on chest imaging, and
diagnosis was ascertained either by broncho-alveolar lavage indicating the presence of hemosiderin-laden
macrophages (19/25 cases), or lung biopsy (6/25). In screened patients, initial auto-immune screening revealed positive
antineutrophilic cytoplasmic antibodies (ANCA) (n = 6, 40%), antinuclear antibodies (ANA) (n = 5, 45%) and specific
coeliac disease antibodies (n = 4, 28%). All the patients were initially treated by corticosteroids. In 13 cases,
immunosuppressants were introduced due to corticoresistance and/or major side effects. Median length of follow-up
was 5.5 yrs, with a satisfactory respiratory outcome in 23/25 patients. One patient developed severe pulmonary fibrosis,
and another with Down syndrome died as a result of severe pulmonary hemorrhage.
Conclusion: The present cohort provides substantial information on clinical expression and outcomes of pediatric IPH.
Analysis of potential contributors supports a role of auto-immunity in disease development and highlights the
importance of genetic factors.
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Idiopathic pulmonary hemosiderosis (IPH) is a rare cause
of alveolar hemorrhage of unknown etiology in children,
leading to chronic infiltrative pulmonary disease [1-4]. It
is classically characterized by a triad of hemoptysis,
iron-deficiency anemia and pulmonary infiltrates on
chest X-rays; and usually occurs before the age of
10 years (yrs) old [5-10]. The diagnosis of IPH is confirmed
by bronchoscopy with bronchoalveolar lavage (BAL) sho-
wing hemosiderin-laden macrophages called siderophages,
pathognomonic of the disease [11]. Lung biopsies are
sometimes required to eliminate differential diagnoses such
as vasculitis [12]. First line treatments usually include sys-
temic corticosteroid therapy. This may be substituted by
immunosuppressants in case of corticosteroid resistance or
dependence and/or unfavorable outcome [2,3,13,14].
Various hypotheses have been proposed to explain the
pathophysiology of IPH: allergic, environmental, genetic
and/or auto-immune. The allergic hypothesis is based
on the frequent association between IPH and cow’s milk
allergy [15]. The environmental theory has been sug-
gested after the emergence of IPH in children exposed
to Stachybotris chartarum [16,17]. IPH has also been de-
scribed in siblings, leading to discuss a genetic theory,
but no gene has yet been identified [18,19]. Finally, the
auto-immune theory is recognized as the most probable,
considering the frequent association with auto-immune
diseases such as coeliac disease, glomerulonephritis
and/or rheumatoid arthritis [2,5,11,17,20-23].
Pediatric IPH is a rare respiratory disease whose inci-
dence varies between 0.24 and 1.26 per million [3]. This
explains the limited knowledge on physiopathology and the
lack of consensus regarding care. Through the organization
of the French Reference Center for Rare Lung Diseases
(RespiRare®) with the national network/web-linked database
(described previously), we reviewed the IPH cases in the
French pediatric population with two main goals: to update
management strategies and to provide new insights into
disease contributors and physiopathology [24].
Material and methods
Since 2008, the RespiRare® database has been set up in
12 French pediatric respiratory centres. This database is
structured as a medical recording tool for the patient,
with extended disease-specific datasets containing clinical
information relevant to all kinds of rare lung diseases
including interstitial lung disease and IPH [24]. The
database and the data collection have been approved
by French national data protection authorities [24].
Each patient and/or his legal representatives are informed
prior to entering their data into the database. This study is
a chart based retrospective study. Relevant clinical data of
the French pediatric IPH patients were retrospectively
collected via the RespiRare® database. Diagnosis is basedon the triad of iron deficiency anemia, respiratory
symptoms (including dyspnea, cough and hemoptysis),
and pulmonary infiltrates on chest imaging, and is con-
firmed by the presence of hemosiderin laden macrophages
in the BAL and/or on lung tissue specimens.
At diagnosis, the data collected comprised:
(i) clinical features: age, body mass index (BMI),
hemoptysis, dypnea, cough and/or febrile
pneumonia; personal and/or familial history of
allergy and/or auto-immune diseases;
(ii) imaging data: chest X-ray and chest CT scan;
(iii)respiratory function tests: spirometry
measurements (vital capacity (VC), forced vital
capacity (FVC), slow vital capacity (SVC) and forced
expiratory volume in one second (FEV1)) and
single-breath measure of carbon monoxide
diffusion (DLCO);
(iv)BAL: the percentage of hemosiderin laden
macrophages, and the Golde score. The Golde score
is a semi-quantitative method for assessing the
hemosiderin content of alveolar macrophages after
Prussian blue stain: at least 200 alveolar macrophages
are examined and, to each macrophage, is attributed a
score ranging from 0 (absence of blue staining) to 4
(hemosiderin laden macrophages); the Golde score
represents the mean score on 100 macrophages
(that could range from 0 to 400). An alveolar
hemorrhage is confirmed for a score higher than 20,
and characterized as severe for a score above 100 [20];
(v) lung biopsy;
(vi) blood tests: hemoglobin, reticulocytes count, and
autoimmune assessments: antitransglutaminase
(ATA, IgA and IgG), antigliadin (AGA) and
antiendomysium (AEA) antibodies, antinuclear
antibodies (ANA), anti-double strand DNA and
anti-smooth-muscle antibodies (SMA), rheumatoid
factor (RF) and antineutrophilic cytoplasmic
antibodies (ANCA).
The data collected during the follow up included treat-
ments, side effects and clinical outcome.
Descriptive data analysis (medians and standard devia-
tions for quantitative values, percentages for qualitative
values) have been realised using the Excel 2010 software.
Results
Population demographic description at diagnosis
Twenty-five patients (20 girls and 5 boys), diagnosed with
IPH between 1996 and June 2012, have been included
from 12 French pediatric respiratory centers. The main
clinical data at diagnosis are described in Table 1.
Median age at diagnosis was 4.3 [0.8-14.0] yrs. Diagnosis
was made before the age of 2 yrs in 7 patients, and after





Febrile pneumonia 11 44
Anemia 16 64
Severe anemia (<7 g/dl) 9 36
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[13.3-25.5] with a median Z-score of −0.6 [−2.46-2.16].
The main manifestations at diagnosis were: dyspnea
(n = 17, 68%), cough (n = 12, 48%), febrile pneumonia
(n = 11, 44%) and hemoptysis (n = 11, 44%). Five patients
out of the 25 IPH cases had a concomitant Down
syndrome (20%).
Among the 25 patients, 2 had a personal history of
coeliac disease and one of arthralgia. Five familial cases
of autoimmune diseases were observed: 2 ankylosing
polyarthritis, 1 coeliac disease, 1 telangiectasis, 1 type 1
diabetes, and one Minkowski-Chauffard disease. Fur-
thermore, 2 patients were dizygote twins and another
patient had 2 cousins with an IPH history.
Investigations at diagnosis
Blood count
Anemia was present in 64% of cases, with a median
hemoglobin of 7.2 g/dl [2.3-12.4]. Nine patients had a
severe anemia (<7 g/dl). Reticulocytes, documented in
only 4 out of the 25 patients, were systematically elevated,
varying between 98,900 and 152,150/mm3.
Thoracic imaging
Interstitial and/or alveolar interstitial patterns were
visualized by chest X-rays for 13 patients and by
chest CT-scans for 17 patients. The chest CT scans
showed ground-glass opacities (12 patients), sub pleural
cysts (6 patients), and, less frequently, micronodules
(2 patients), thickened interlobular septa (2 patients),
honeycomb patterns (1 patient), and traction bronchiectasis
(1 patient). Images were often diffuse and bilateral.
An illustration is given in Figure 1.
Respiratory function tests
Spirometric analyses at onset were available for 18
patients. The 7 remaining patients had less than 3 yrs
old at the time of diagnosis, and, thus, did not per-
form functional respiratory tests. The spirometric analyses
were normal in 9/18 patients (50%), showed a restrictive
pattern for 6 patients (37.5%) and an airway obstruction
for 1 patient (6%). Medians of VC, FVC and SVC were re-
spectively 69, 70 and 65%. For the patients presenting witha restrictive pattern, the median age was 9 yrs old [3].
DLCO, measured for 9 patients, was either decreased
(4/9: 44%), or normal.
BAL
The diagnosis was ascertained in 19/25 cases by the
BAL that showed an accumulation of hemosiderin-laden
macrophages. The Golde score, evaluated in 7 cases
indicated a median of 158 [52–356].
Pulmonary biopsies
Eight patients underwent a lung biopsy, which documented
presence of red blood cells in the alveoli and in the
interstitium.
Auto immune assessments
Results of the initial auto-immune screenings are
described in Table 2. In screened patients, it principally
revealed positive ANCA (n = 6, 40%), ANA (n = 5, 45%),
ASM (n = 3, 50%), and specific cow’s milk IgE (n = 3, 33%).
Specific coeliac disease antibodies were screened in
14 patients (56%), and found to be positive in 4 (28%
of the tested patients): 3 patients had positive ATA
IgA, and 1 positive AGA.
During the follow-up, additional auto-antibodies were
documented: RF (n = 3) and ANA (n = 2). Interestingly,
repeated evaluation of the auto-immune status in the
6 positive ANCA patients showed variable evolution:
ANCA disappeared for 4 patients at the end of the
follow-up, decreased for one patient and remained
stable for one patient.
Treatment and follow up
Treatment synopsis is described Figure 2. As highlighted,
all the patients received systemic corticosteroids with a
variable efficacy. Intravenous corticosteroids were the usual
first line treatment with monthly pulses of methylpredniso-
lone (300 mg/m2/day for 3 days per month) for 100% of
the patients (n = 25). In situations of severe symptoms, daily
oral prednisone was added (1 mg/kg/d). The duration of
corticosteroids treatment was variable among the patients
based on clinical, radiological (alveolar infiltrates) and
biological (hemoglobin, reticulocytes) evolution.
Thirteen patients had an unsatisfactory outcome, inclu-
ding in 6 of them a Cushing syndrome with important gain
of weight, stretch marks and hyperthricosis. For these 13
patients, one or more immunosuppressants were added:
hydroxychloroquine (4.5 to 6 mg/kg/day for n = 10
patients), mycophenolate mofetil (600 mg/m2/day for
n = 7 patients), or azathioprine (1 mg/kg/day for n = 1
patient). No side effects were reported, allowing either
to interrupt the corticosteroids (n = 6 patients), or to
reduce their dosage (n=7 patients).
a b
Figure 1 Thoracic imaging. a shows ground-glass opacities on a chest X-ray in a 5 yrs old IPH patient. b shows on a chest CT-scan an
interstitial pattern with micronodules and ground-glass opacities in a 5 yrs old IPH patient.
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14 yrs). Respiratory outcome was satisfactory in 23 patients,
although 7 of them experienced several relapses. The 2
other patients, who were diagnosed at 5 months old, had a
severe expression of the disease: 1 of them developed
a pulmonary fibrosis, and the other one (with a Down
syndrome) had a fatal pulmonary hemorrhage.
Discussion
Although several pediatric IPH cases have been reported
in the literature, few cohorts have been described so far.
To our knowledge, this study is one of the largest ever
reported, with 25 IPH pediatric cases, and a long median
length of follow-up of 5.5 yrs [25].
IPH generally occurs in children below the age of
10 yrs, and commonly between the ages of 1–7 yrs
[2,5,8,21]. Although the classical triad of iron deficiency
anemia, respiratory symptoms (including dyspnea, cough
and hemoptysis), and pulmonary infiltrates on chest
imaging is characteristic, clinical presentation is highlyTable 2 Auto-immune assessment at diagnosis
Tested (n) Positive (n) Positive (%)
Coeliac disease Ig 14 4 28
Cow's milk allergy 9 3 33
ANCA 15 6 40
Anti nuclear antibodies 11 5 45
Anti smooth muscle antibodies 6 3 50
Rheumatoid factor 10 2 20




Ig: immunoglobulin, ANCA: anti neutrophilic cytoplasmic antibodies,
ds: double strandvariable; anemia and dyspnea being the most frequent
clinical features (64% and 68% respectively in our study).
Hemoptysis only occurred in 50% of the patients, but its
incidence could be underestimated in young children,
who frequently swallow their sputum. So far, number of
studies highlighted an important delay between onset of
symptoms and IPH diagnostic, ranging from 1 to 6.3 yrs
[3,7,11,14,21]. In our study, the highest delay reached
16 months. This delay in diagnosis may be due to several
factors: insidious onset, and lack of awareness about the
condition. Moreover, iron deficiency anemia can also be
misleading, especially if respiratory signs are mild.
IPH pathogenesis remains controversial, with, so far, four
main etiological hypotheses described in the literature: the
environmental, the allergic, the auto-immune, and the
genetic hypotheses. In this cohort, we found no evidence
favouring an environmental etiology, with, however, little
collected information on the various possible environmen-
tal factors. This theory was suggested after the occurrence
of acute pulmonary hemorrhages in children exposed to
Stachybotris chartarum in Cleveland, but was not further
confirmed [16,17]. Similarly, the allergic theory, based on
the association with the hypersensitivity to proteins in
cow's milk (Heiner syndrome), remains controversial [15].
In the present cohort, 3 patients out of 25 had positive
antibodies. As eviction of cow's milk proteins has been
shown to benefit the patients with Heiner syndrome, the
dosage of cow's milk IgE remains recommended.
Our present study provides support for an auto-immune
contribution in IPH physiopathology. First, most of the
patients (17 out of the 25) had auto-immune antibodies at
onset, and, for 6 patients, additional auto-immune anti-
bodies appeared during the follow-up. The most frequent
auto-immune antibodies that were found in our cohort














Figure 2 Treatment synopsis.
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with primitive vasculitis and systemic diseases, and
rarely reported in IPH patients in the literature
[26,27]. Furthermore, several authors described that
one out of 4 children with IPH who survive develops
an immune disorder [21,22]. In their IPH cohort, Le
Clainche et al. reported 3 patients out of 15 who
displayed rheumatoid arthritis-like symptoms, 6 months
to 7 yrs after IPH diagnosis [21]. In our study, the search
for RF, performed in 10 patients, gave a positive result in 2
of them. Rheumatoid arthritis is known to be the most
frequent systemic disease in the general population
(0.5 to 1%) and arthritis is sometimes associated with
respiratory symptoms, typically with a diffuse parenchymal
lung disease [1]. This would suggest to systematically screen
IPH patients for rheumatoid arthritis. Moreover, along with
the dosage of RF, we propose to associate the research of
anti-citrullinated peptides (anti-CCP). Indeed, several stu-
dies have led to suggest that anti-CCPs may be more spe-
cific and appear earlier in the course of rheumatoid arthritis
than the classical auto-antibodies, even in the absence of
clinical manifestations of rheumatoid arthritis or connective
tissue disease [28,29]. Of interest, the levels of anti-CCPs
were reported to strongly correlate with the variation in
DLCO, and possibly to lung disease severity [30].
IPH has frequently been associated with the celiac
disease, another auto-immune disorder. This association
is well-known as the Lane-Hamilton syndrome, with 14
cases described in the literature [31,32]. In the present
study, specific celiac disease anti-bodies (anti-gliadin,
anti-endomysium and anti-transglutaminase antibodies)
were indeed present in 4 patients among the 14 patients
tested (i.e. 28% of the tested patients). As a gluten-free
diet has been proven beneficial to the evolution of the
celiac disease, as well as to the respiratory outcome of the
patients with a Lane-Hamilton syndrome, we recommenda systematic screening for celiac disease in IPH patients.
Some authors even suggest to systematically perform
gastrointestinal endoscopies and biopsies in IPH patients
for whom the severity of anemia is disproportionate
to radiological findings, even in the absence of gastrointes-
tinal symptoms [7,31]. In addition, it may be worth to
include HLA screening to the panel of tests performed in
IPH situations. Indeed, HLA DQ2 is present in 90 to 95%
of the patients presenting with a celiac disease [33,34].
Information derived from the present cases analysis
supports a role of genetic contribution to IPH expres-
sion. Two of the patients were dizogote twins, 2
others had relatives with IPH, and 7 had a personal
and/or a familial history of auto-immune disorders.
An exhaustive research for family history will help de-
veloping appropriate genetic studies. We were sur-
prised to find a high prevalence of Down syndromes
in our cohort (5 patients out of 25, i.e. 20%), the
prevalence of the Down syndrome in the French
population being 1/2,000 birth per year. To our
knowledge, no study had previously reported such an
association, which may provide important insights
into IPH physiopathology. Indeed, it is known that
Down syndrome patients have more frequent auto-
immune diseases, with a particular high frequency of
celiac disease [35-38]. In our cohort, among the 4 patients
tested positive for celiac disease antibodies, 2 had a Down
syndrome. Furthermore, we observed that the Down’s syn-
drome patients with IPH had a worst prognosis compared
to the others, including the patient with a fatal outcome,
and the 4 others who experienced frequent relapses.
One possible explanation may be the higher frequency
of lower respiratory tract infections in Down syn-
drome patients, possibly linked to lower IgG2 serum
levels, lower lymphocytes’ count, and/or lower T and
NK lymphocytes counts [39].
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IPH with various results [3,5,13]. Disease rarity precludes
the set-up of randomized controlled trials to evaluate the
efficacy of immunomodulatory and/or anti-inflammatory
agents for IPH. As indicated in small case series and/or
case reports, the main treatments are corticosteroids with
various regimens. Corticosteroids have been reported to
be associated with decreased pulmonary bleeding relapses
and pulmonary fibrosis progression, as well as with higher
survival rates [5]. Therapeutic regimens vary across the
studies. Immunosuppressive therapies, mainly azathioprine
and hydroxychloroquine, are mostly proposed in situations
of patients with steroid-refractory disease [3,14,17,21,40,41].
Similar therapeutical strategies were observed in the
present cohort, with mainly corticosteroids at diagnosis,
then introduction of hydroxychloroquin or mycophenolate
mofetil in situations of cortico-dependence and or resis-
tance. In the literature, 2 cases of lung transplantation were
reported, but both experienced a recurrence of bleeding
within the allograft [40,41].
The major strengths of the present study are the large
size of the cohort, with 25 IPH pediatric cases, and the
long follow-up, with a median of 5.5 yrs. The largest
pediatric cohort published so far was from India, with
26 children with IPH, but with a shorter length of
follow-up (mean: 28 ± 27 months) [25]. These strengths
have been achieved thanks to the RespiRare® database,
which offers a unique opportunity to collect clinical, bio-
logical and radiological data from patients with rare respira-
tory disorders followed in French pediatric respiratory
expert centers. This study has, however, limitations, mainly
the heterogeneity in investigation protocols and therapeutic
regimens. This is a major challenge that will be efficiently
addressed with the set-up of the RespiRare® network and
the establishment of common procedures of IPH patient
management.
To conclude, the review of this large pediatric cohort
leads to suggest a probable concomitant auto-immune
and genetic etiology of IPH. This implies that a systematic
screening for auto-immune diseases should be included in
the diagnostic procedure. An important finding is also the
high number of IPH patients with Down syndrome, that
will need to be further investigated. Furthermore, a struc-
tured follow-up including blood tests with reticulocyte
counts is critical to improve patient management and to
allow an earlier diagnosis and treatment of exacerbations.
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